|
8 Companies |
|
6 Products |
|
6 Products |
|
13 Mechanisms of Action |
|
0 Trials |
|
23 News |
|
- | NN1213 / Novo Nordisk
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: LUVIA: The Effects of Lutein and Zeaxanthin Supplementation on Vision in Patients With Albinism (clinicaltrials.gov) - Dec 28, 2018
P=N/A, N=10, Completed, Sponsor: Johns Hopkins University
Recruiting --> Completed | N=28 --> 10 | Trial completion date: Dec 2018 --> Apr 2018 | Trial primary completion date: Dec 2018 --> Apr 2018
- | Trial primary completion date: LUVIA: The Effects of Lutein and Zeaxanthin Supplementation on Vision in Patients With Albinism (clinicaltrials.gov) - Dec 14, 2017
P=N/A, N=28, Recruiting, Sponsor: Johns Hopkins University
Recruiting --> Completed | N=28 --> 10 | Trial completion date: Dec 2018 --> Apr 2018 | Trial primary completion date: Dec 2018 --> Apr 2018 Trial primary completion date: Sep 2017 --> Dec 2018
- | pirfenidone / Generic mfg.
Trial completion: Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome (clinicaltrials.gov) - Oct 15, 2017
P2, N=35, Completed, Sponsor: William Gahl, M.D.
Trial primary completion date: Sep 2017 --> Dec 2018 Active, not recruiting --> Completed
- Trial completion: Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients (clinicaltrials.gov) - Apr 4, 2017
P4, N=10, Completed, Sponsor: Netherlands Institute for Pigment Disorders
Active, not recruiting --> Completed Enrolling by invitation --> Completed
- Orfadin (nitisinone) / Astellas, SOBI
Trial primary completion date: Nitisinone for Type 1B Oculocutaneous Albinism (clinicaltrials.gov) - Jan 31, 2017
P1/2, N=5, Active, not recruiting, Sponsor: National Eye Institute (NEI)
Enrolling by invitation --> Completed Trial primary completion date: Dec 2017 --> Jul 2016
- Orfadin (nitisinone) / Astellas, SOBI
Enrollment closed, Enrollment change, Trial primary completion date: Nitisinone for Type 1B Oculocutaneous Albinism (clinicaltrials.gov) - Sep 15, 2016
P1/2, N=5, Active, not recruiting, Sponsor: National Eye Institute (NEI)
Trial primary completion date: Dec 2017 --> Jul 2016 Recruiting --> Active, not recruiting | N=50 --> 5 | Trial primary completion date: Dec 2016 --> Dec 2017
- metformin / Generic mfg.
New P4 trial, IO biomarker: Apoptotic Signaling Pathways in Rats With Endometrial Hyperplasia (clinicaltrials.gov) - Aug 18, 2016
P4, N=40, Completed, Sponsor: Kayseri Education and Research Hospital
- Orfadin (nitisinone) / Astellas, SOBI
Trial primary completion date: Nitisinone for Type 1B Oculocutaneous Albinism (clinicaltrials.gov) - Oct 7, 2015
P1/2, N=50, Recruiting, Sponsor: National Eye Institute (NEI)
Recruiting --> Active, not recruiting | N=50 --> 5 | Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Dec 2015 --> Dec 2016
- New P4 trial: Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients (clinicaltrials.gov) - Jun 1, 2015
P4, N=10, Enrolling by invitation, Sponsor: Netherlands Institute for Pigment Disorders
- Enrollment open: LUVIA: The Effects of Lutein and Zeaxanthin Supplementation on Vision in Patients With Albinism (clinicaltrials.gov) - Jan 26, 2015
P=N/A, N=28, Recruiting, Sponsor: Johns Hopkins University
Trial primary completion date: Dec 2015 --> Dec 2016 Not yet recruiting --> Recruiting
- Trial completion, Trial primary completion date: Trial of L-DOPA as a Treatment to Improve Vision in Albinism (clinicaltrials.gov) - Dec 12, 2014
P2, N=47, Completed, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Dec 2014
- Clinical: LUVIA: The Effects of Lutein and Zeaxanthin Supplementation on Vision in Patients With Albinism (clinicaltrials.gov) - Jul 25, 2014
P=N/A, N=28, Not yet recruiting, Sponsor: Johns Hopkins University
- Orfadin (nitisinone) / Astellas, SOBI
Enrollment open: Nitisinone for Type 1B Oculocutaneous Albinism (clinicaltrials.gov) - Feb 18, 2014
P1/2, N=8, Recruiting, Sponsor: National Eye Institute (NEI)
Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Dec 2014 Not yet recruiting --> Recruiting
- Orfadin (nitisinone) / Astellas, SOBI
New P1/2 trial: Nitisinone for Type 1B Oculocutaneous Albinism (clinicaltrials.gov) - Apr 22, 2013
P1/2, N=8, Recruiting, Sponsor: National Eye Institute (NEI)
- Enrollment closed: Trial of L-DOPA as a Treatment to Improve Vision in Albinism (clinicaltrials.gov) - Feb 27, 2013
P2, N=45, Active, not recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / AbbVie
Trial withdrawal: Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome (clinicaltrials.gov) - Jan 24, 2013
P2, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Terminated --> Withdrawn
- Zyflo (zileuton) / Chiesi
Trial termination: Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome (clinicaltrials.gov) - Nov 7, 2012
P1/2, N=3, Terminated, Sponsor: National Human Genome Research Institute (NHGRI)
Terminated --> Withdrawn Recruiting --> Terminated; insufficient enrollment
- Zyflo (zileuton) / Chiesi
Enrollment change: Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome (clinicaltrials.gov) - Nov 7, 2012
P1/2, N=3, Terminated, Sponsor: National Human Genome Research Institute (NHGRI)
Recruiting --> Terminated; insufficient enrollment N=12 --> 3
- pirfenidone / Generic mfg.
Enrollment closed: Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome (clinicaltrials.gov) - Jan 23, 2012
P2, N=35, Active, not recruiting, Sponsor: William Gahl
N=12 --> 3 Terminated --> Active, not recruiting
- pirfenidone / Generic mfg.
Trial initiation date: Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome (clinicaltrials.gov) - Dec 4, 2011
P2, N=35, Active, not recruiting, Sponsor: William Gahl
Terminated --> Active, not recruiting Initiation date: Mar 1997 --> Sep 2005
- pirfenidone / Generic mfg.
Enrollment change: Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome (clinicaltrials.gov) - Dec 4, 2011
P2, N=35, Active, not recruiting, Sponsor: William Gahl
Initiation date: Mar 1997 --> Sep 2005 N=58 --> 35